Google DeepMind, Meta, and AI drug discovery startup Isomorphic Labs are jointly investing $300 million into Biohub, the nonprofit biomedical research organization founded by Mark Zuckerberg and Priscilla Chan. This funding is a core component of a $1.8 billion initiative designed to build AI datasets that allow researchers to simulate biological questions digitally, potentially uncovering new methods to prevent and manage diseases.
The Vision of a Virtual Cell
Founded in 2016, Biohub’s primary mission is to combat diseases through the development of a “virtual cell.” This platform will enable researchers to carry out complex digital simulations. Alex Rives, Biohub’s head of science, emphasized that an accurate predictive model of biology could dramatically accelerate scientific discovery by allowing experiments to be performed in a digital environment.
A Large-Scale Public-Private Partnership
The project is not limited to private tech investment. The US Department of Energy is set to invest over $500 million over the next five years. Additionally, the National Institutes of Health (NIH) will provide datasets and knowledge bases derived from previous federal investments totaling more than $500 million. Rives noted that the creation of a virtual cell is one of the most significant challenges for the next era of science, requiring coordinated data efforts on a global scale.
